<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800433</url>
  </required_header>
  <id_info>
    <org_study_id>pentoxifylline in hemodialysis</org_study_id>
    <nct_id>NCT03800433</nct_id>
  </id_info>
  <brief_title>Pentoxifylline Administration in Hemodialysis Patients</brief_title>
  <official_title>Impact of Pentoxifylline Administration on the Modulation of Hyporesponsiveness to Erythropoietin Stimulating Agents in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the impact of pentoxifylline administration on the
      modulation of hyporesponsiveness to erythropoietin stimulating agents in hemodialysis
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this is a prospective, randomized, controlled study to assess the impact of pentoxifylline
      administration on the modulation of hyporesponsiveness to erythropoietin stimulating agents
      in hemodialysis patients by determining several outcomes from the intervention and control
      groups at the end of the study.These outcomes include;the difference in hemoglobin and
      hematocrit concentration , the difference in inflammatory markers tumor necrosis factor Alpha
      (TNF-α), interleukin-1 Beta (IL-1β),the difference in the dosage of erythropoiesis
      stimulating agents ,and The erythropoietin stimulating agents (ESA) resistance index (ERI).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in hemoglobin and hematocrit concentration between the intervention and control groups at the end of the study</measure>
    <time_frame>up to 6 months post baseline</time_frame>
    <description>Patients will be evaluated regularly every month for hemoglobin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety &amp; tolerability of pentoxifylline ( frequency of adverse drug effects due to Pentoxifylline as well as compliance with pentoxifylline).</measure>
    <time_frame>up to 6 months post baseline</time_frame>
    <description>Patients will be evaluated regularly for frequency of adverse drug effects due to Pentoxifylline as well as compliance with pentoxifylline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers TNF-a, IL-1β.</measure>
    <time_frame>up to 6 months post baseline</time_frame>
    <description>patient will be subjected to laboratory evaluation for estimation of IL-1β,TNF-α levels at baseline as well as end of study evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the dosage of erythropoiesis stimulating agents.</measure>
    <time_frame>up to 6 months post baseline</time_frame>
    <description>the dose of ESA will be assessed at end of study evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ESA ( erythropoiesis stimulating agents)resistance index (ERI).</measure>
    <time_frame>up to 6 months post baseline</time_frame>
    <description>ERI will be assessed for patients by determining ESA dose and hemoglobin concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Anemia Renal</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trental 400 MG Extended Release Oral Tablet</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years or over).

          -  Stable hemodialysis &gt;6 months.

          -  Regular haemodialysis (3 times/ week).

          -  ESA resistant anemia (Hb &lt;10 mg/dl for 6 mo.).

          -  ESA dose of &gt;8000 IU/wk.

        Exclusion Criteria:

          -  Inadequate hemodialysis.

          -  Hyperparathyroidism (PTH&gt;800 pg/l).

          -  Known hypersensitivity to, or intolerance of Pentoxifylline.

          -  Absolute or functional iron deficiency (ferritin &lt; 100 μg/L and/or transferrin
             saturation &lt; 20%).

          -  Presence of systemic haematological disease (including antibody-mediated pure red cell
             aplasia) or known haemoglobinopathy.

          -  Major surgery, infection, inflammatory diseases, acute myocardial infarction or
             malignancy within the last 3 months.

          -  Patients with chronic liver disease and patients who had received immunosuppressive
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lamia El Wakeel, Ass.Prof</last_name>
    <role>Study Director</role>
    <affiliation>Ass.prof clinical pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radwa El Borolossy, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of clinical pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy ElSharkawy, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prof. of nephrology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Radwa M Elmetwaly, Bachelor</last_name>
    <phone>00201065371016</phone>
    <email>radwa_mohm@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011-23. Review.</citation>
    <PMID>15758012</PMID>
  </reference>
  <reference>
    <citation>Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007 Aug;12(4):321-30. Review.</citation>
    <PMID>17635745</PMID>
  </reference>
  <reference>
    <citation>Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004 Jul;15(7):1877-82.</citation>
    <PMID>15213276</PMID>
  </reference>
  <reference>
    <citation>Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton). 2010 Apr;15(3):344-9. doi: 10.1111/j.1440-1797.2009.01203.x.</citation>
    <PMID>20470305</PMID>
  </reference>
  <reference>
    <citation>Goicoechea M, García de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, Panizo N, Verde E, Muñoz MA, Luño J. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012 Nov-Dec;25(6):969-75. doi: 10.5301/jn.5000077.</citation>
    <PMID>22241639</PMID>
  </reference>
  <reference>
    <citation>Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol. 2015;185:76-86. doi: 10.1159/000380972. Epub 2015 May 19. Review.</citation>
    <PMID>26023017</PMID>
  </reference>
  <reference>
    <citation>Shahbazian H, Ghorbani A, Zafar-Mohtashami A, Balali A, AleAli A, Lashkarara GR. Administration of pentoxifylline to improve anemia of hemodialysis patients. J Renal Inj Prev. 2016 Nov 26;6(1):61-64. doi: 10.15171/jrip.2017.11. eCollection 2017.</citation>
    <PMID>28487874</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Radwa Mohamed Elmetwaly</investigator_full_name>
    <investigator_title>Post grad</investigator_title>
  </responsible_party>
  <keyword>pentoxifylline</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

